September 2025
1. FRISONI GB, Hansson O, Nichols E, Garibotto V, et al
   New landscape of the diagnosis of Alzheimer's disease.
   Lancet. 2025;406:1389-1407.
   

   >> Share

   
   April 2025
2. FERDINANDUS J, Schneider G, Borchmann P
   PET evaluation in Hodgkin lymphoma: when to change treatment - Authors' reply.
   Lancet. 2025;405:1145.
   

   >> Share

   
   
3. SHIMAZU Y
   PET evaluation in Hodgkin lymphoma: when to change treatment.
   Lancet. 2025;405:1144-1145.
   

   >> Share

   
   March 2025
4. PEREZ-GARCIA JM, Gebhart G, Rodriguez-Morato J, Llombart-Cussac A, et al
   Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors' reply.
   Lancet. 2025;405:1055-1056.
   

   >> Share

   
   
5. HINDIE E, Groheux D
   Neoadjuvant therapy in HER2-positive breast cancer and interim PET.
   Lancet. 2025;405:1054-1055.
   

   >> Share

   
   July 2024
6. EVENS AM
   Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphoma.
   Lancet. 2024;404:312-313.
   

   >> Share

   
   
7. BORCHMANN P, Ferdinandus J, Schneider G, Moccia A, et al
   Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
   Lancet. 2024 Jul 3:S0140-6736(24)01315-1. doi: 10.1016/S0140-6736(24)01315.
   

   >> Share

   
   April 2024
8. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
   3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
   Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
   

   >> Share

   
   February 2024
9. BAYAS A, Menacher M, Lapa C, Tappe D, et al
   (18)fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI changes in Borna disease virus 1 encephalitis.
   Lancet. 2024;403:665-666.
   

   >> Share

   
   December 2023
10. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share